Floatz logo

Cyclophosphamide

Pancreatic Ductal Adenocarcinoma

Explore 280 assets in Pancreatic Ductal Adenocarcinoma →
Floatz Rating
B61/100
Confidence
Indicative
v0.2
Sponsor
City of Hope Medical Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT06626256CT.gov
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
—Withdrawn———
NCT04809766CT.gov
Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
—Terminated———
NCT04146298CT.gov
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
—Recruiting———
NCT04025216CT.gov
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
—Terminated———
NCT03610490CT.gov
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
—Terminated———
NCT07614048CT.gov
Intermediate-size IND for Treatment of Patients With Advanced Cancer Using T Cells Engineered to Express TCR Targeting Mutant KRAS
—Temporarily Not Available———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Pancreatic Ductal Adenocarcinoma

AssetSponsorPhaseRating
Cyclophosphamide (this asset)City of Hope Medical CenterP2B · 61
Rmc-6236Tango Therapeutics, Inc.P3BB
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, DimerOHSU Knight Cancer InstituteP2BB
DaraxonrasibRevolution Medicines, Inc.P3BB
S-1Genentech, Inc.P2BB
OxaliplatinJonsson Comprehensive Cancer CenterP4BB
MetforminBritish Columbia Cancer AgencyP2BB
IvospeminPanbela Therapeutics, Inc.P2/3BB
(R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)MethanoneCorcept TherapeuticsP3BB

+42 more in the Pancreatic Ductal Adenocarcinoma cohort

Other indications for Cyclophosphamide

IndicationSponsorPhaseRating
Adult Acute Lymphoblastic Leukemia—P4BBB · 79
Mycosis Fungoides—P4BBB · 78
B-Cell Childhood Acute Lymphoblastic Leukemia—P3BBB · 78

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Cyclophosphamide in Pancreatic Ductal Adenocarcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/cyclophosphamide-pancreatic-ductal-adenocarcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →